Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LXRX bears and bulls Lexicon Pharmaceuticals Inc Nasdaq Lxrx Short Squeeze
Probably the sell on news thing eh?
I hear you been buying and selling bios and pharmas for years.
Don’t buy this POS I lost money here this morning. Crap ticker
LXRX 3.96
News: $LXRX Cancer Drug Revenues Expected to be Largest Share in Pharma Market
December 9, 2019 Palm Beach, FL –December 9, 2019 – One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8 Mn ...
In case you are interested LXRX - Cancer Drug Revenues Expected to be Largest Share in Pharma Market
* * $LXRX Video Chart 12-06-2019 * *
Link to Video - click here to watch the technical chart video
Closed a lot of the upward gap. Thought it was going to go for it!
Patience.
* * $LXRX Video Chart 12-05-2019 * *
Link to Video - click here to watch the technical chart video
News: $LXRX Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211
THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in developm...
In case you are interested LXRX - Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211
* * $LXRX Video Chart 12-04-2019 * *
Link to Video - click here to watch the technical chart video
* * $LXRX Video Chart 11-07-19 * *
Link to Video - click here to watch the technical chart video
* * $LXRX Video Chart 10-07-2019 * *
Link to Video - click here to watch the technical chart video
3 Penny Stocks Making Interesting Moves With High Volume in October
$RESN $PESI $LXRX
https://www.transparenttraders.me/2019/10/3-penny-stocks-making-interesting-moves.html
* * $LXRX Video Chart 09-30-2019 * *
Link to Video - click here to watch the technical chart video
it will come like that-there will be a change in the PIPELINE too
Chart showing an inversion forming, could break through resistance of 3.75.
Clay was right again---GREEN
* * $LXRX Video Chart 09-25-2019 * *
Link to Video - click here to watch the technical chart video
Clay was right again---GREEN
That’s right....
LXRX will be resuming its climb shortly. All passengers buckle your seatbelts and enjoy your Quid’s assent!
* * $LXRX Video Chart 09-19-2019 * *
Link to Video - click here to watch the technical chart video
* * $LXRX Video Chart 09-18-2019 * *
Link to Video - click here to watch the technical chart video
Look at those Clay videos day after day.
He must be losing his ass on this.
Building nicely here. Wouldn't be surprised to see LXRX get gobbled up.
* * $LXRX Video Chart 09-17-2019 * *
Link to Video - click here to watch the technical chart video
* * $LXRX Video Chart 09-16-2019 * *
Link to Video - click here to watch the technical chart video
* * $LXRX Video Chart 09-12-2019 * *
Link to Video - click here to watch the technical chart video
News: $LXRX Here's Why Lexicon Pharmaceuticals Is Soaring This Week
Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) rose over 15% today and have gained about 90% in the last five days as investors continue to digest the fallout from a major partner walking away. On Sept. 10, the company and Sanofi terminated a collaboration to develop and commercia...
Find out more LXRX - Here's Why Lexicon Pharmaceuticals Is Soaring This Week
$2 low. That may be it, we'll see of course. As a long i'd be fine picking up a few under $2 since I'm looking for $6+.
Me too you aren’t the only one lol had this on my watch list for 6 months
* * $LXRX Video Chart 09-11-2019 * *
Link to Video - click here to watch the technical chart video
Lxrx reversing here. Looking like a multiday runner here.
See just how much of the gap she fills. Should cruise for a few days imo.
Followers
|
55
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
769
|
Created
|
02/27/05
|
Type
|
Free
|
Moderators |
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.
In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.
The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.
“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |